For Healthcare Professionals

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)


About the study

The purpose of this Proof of Concept (PoC) and Dose-finding (DF) basket study is to evaluate the efficacy and safety of orally administered Enpatoran over 24 weeks in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE; subacute cutaneous lupus erythematosus [SCLE] and/or discoid lupus erythematosus [DLE]) participants in a randomized, double-blind, placebo-controlled, parallel, adaptive and dose-ranging setting. Study Duration: 33 weeks Visit Frequency: every 2 or 4 weeks Enpatoran is not available through an expanded access program.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Active CLE (SCLE and/or DLE) with a CLE disease area and activity index (CLASI-A) >= 8
  2. Active SLE with presence of: CLASI-A >= 8 and BILAG 2004 1B, C, D (that is [i.e.], No BILAG 2004 A and No BILAG 2004 >= 2B) or BILAG 2004 >= 1A or 2B and 1 or 2 of the following: Hybrid Safety of Estrogens in Systemic Lupus Erythematosus National Assessment (SELENA)-SLEDAI >= 6 at Screening Visit and confirmed clinical hybrid SELENA-SLEDAI >= 4 (excluding laboratory parameters) at Day 1 Visit and/or CLASI-A >= 8
  3. Receiving a stable dose of at least one of the following standards of care therapies for lupus: Immunomodulator/immunosuppressant, oral corticosteroids, and/or topical corticosteroids
  4. Other protocol defined inclusion criteria could apply


Exclusion Criteria:

  1. Autoimmune or rheumatic disease other than SLE or CLE
  2. Dermatological diseases other than cutaneous manifestations of SLE or CLE
  3. Uncontrolled medical conditions including significant cardiovascular events, active lupus nephritis, and active neurological disorder
  4. Ongoing or active clinically significant viral, bacterial, or fungal infection
  5. History of uncontrolled seizures or other neurological disorder
  6. History of or positive for human immunodeficiency virus, hepatitis C virus, or hepatitis B virus
  7. History of malignancy
  8. Other protocol defined exclusion criteria could apply

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 888-275-7376Email iconEmail Study Center

Study’s details


Systemic Lupus Erythematosus

Age (in years)

18 - 75


Phase 2

Participants needed


Est. Completion Date

Aug 16, 2024

Treatment type



EMD Serono identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.